This benefit of orexin blockade was confirmed in the Tg2576 AD mouse model, in which treatment with an orexin receptor blocker, almorexant, suppressed the normally elevated nocturnal levels of Aβ and reduced plaque accumulation (Kang et al., 2009). Here, HCRT is linked to Alzheimer disease.